[go: up one dir, main page]

BR9811598A - "compostos de carbamilóxi que inibem adesão de leucócito mediada por vla-4". - Google Patents

"compostos de carbamilóxi que inibem adesão de leucócito mediada por vla-4".

Info

Publication number
BR9811598A
BR9811598A BR9811598-7A BR9811598A BR9811598A BR 9811598 A BR9811598 A BR 9811598A BR 9811598 A BR9811598 A BR 9811598A BR 9811598 A BR9811598 A BR 9811598A
Authority
BR
Brazil
Prior art keywords
compounds
leukocyte adhesion
vla
mediated leukocyte
inhibit
Prior art date
Application number
BR9811598-7A
Other languages
English (en)
Inventor
Eugene D Thorsett
Christopher M Semko
Dimitrios Sarantakis
Michael A Pleiss
Anthony Kreft
Andrei W Konradi
Francine S Grant
Darren B Dressen
Susan Ashwell
Reinhardt Bernhard Baudy
Louis John Lombardo
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of BR9811598A publication Critical patent/BR9811598A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS DE CARBAMILóXI QUE INIBEM ADESãO DE LEUCóCITO MEDIADA POR VLA-4"<D>. São descritos compostos que ligam VLA-4. Certos destes compostos também inibem adesão de leucócito e, em particular, adesão de leucócito mediada por VLA-4. Tais compostos são úteis no tratamento de doenças inflamatórias em um paciente de mamífero, por exemplo, ser humano, tais como asma, doença de Alzheimer, ateroesclerose, demência da AIDS, diabetes, doença de intestino inflamatório, artrite reumatóide, transplante de tecido, metástase de tumor e isquemia miocardial. Os compostos podem também ser administrados para o tratamento de doenças do cérebro tal como esclerose múltipla.
BR9811598-7A 1997-07-31 1998-07-31 "compostos de carbamilóxi que inibem adesão de leucócito mediada por vla-4". BR9811598A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90442497A 1997-07-31 1997-07-31
US5445397P 1997-08-01 1997-08-01
PCT/US1998/015324 WO1999006390A1 (en) 1997-07-31 1998-07-31 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
BR9811598A true BR9811598A (pt) 2000-10-03

Family

ID=26733051

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811598-7A BR9811598A (pt) 1997-07-31 1998-07-31 "compostos de carbamilóxi que inibem adesão de leucócito mediada por vla-4".

Country Status (18)

Country Link
EP (3) EP1000051B1 (pt)
JP (3) JP2001502361A (pt)
KR (1) KR100639055B1 (pt)
CN (1) CN1119340C (pt)
AR (1) AR016133A1 (pt)
AT (2) ATE267188T1 (pt)
AU (2) AU8605098A (pt)
BR (1) BR9811598A (pt)
CA (2) CA2290745C (pt)
DE (2) DE69824007T2 (pt)
ES (1) ES2221183T3 (pt)
IL (1) IL133636A0 (pt)
NO (1) NO20000413L (pt)
NZ (1) NZ502578A (pt)
PL (1) PL338521A1 (pt)
RU (1) RU2220964C2 (pt)
TW (1) TW533211B (pt)
WO (2) WO1999006391A1 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP0998282A4 (en) * 1997-05-29 2000-08-30 Merck & Co Inc SULPHONAMIDES AS CELL ADHESION INHIBITORS
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
DE69818049T2 (de) 1997-06-23 2004-07-15 Tanabe Seiyaku Co., Ltd. Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
CA2290750A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6337340B1 (en) * 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CZ20012361A3 (cs) 1999-01-22 2001-12-12 Elan Pharmaceuticals, Inc. Metoda pro léčení nemoci zprostředkované VLA-4, sloučenina a farmaceutický prostředek
US6545003B1 (en) * 1999-01-22 2003-04-08 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2000043369A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2002538135A (ja) 1999-03-01 2002-11-12 エラン ファーマシューティカルズ，インコーポレイテッド α４β７レセプターアンタゴニストとして有用なα−アミノ酢酸誘導体
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
WO2001010837A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent sulfonamides
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
WO2001074769A1 (en) * 2000-03-27 2001-10-11 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
EE200200555A (et) * 2000-03-27 2004-06-15 Applied Research Systems Ars Holding N.V. Farmatseutiliselt aktiivsed pürrolidiini derivaadid
JP2003531141A (ja) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド エナミン誘導体
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
WO2002004426A1 (en) 2000-07-07 2002-01-17 Celltech R & D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
DE10155075A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
UA78021C2 (en) * 2002-03-28 2007-02-15 Applied Research Systems Thiazolidine carboxamide derivatives as modulators of prostaglandine f receptors
PL373763A1 (en) * 2002-04-30 2005-09-19 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
MXPA05007843A (es) * 2003-01-24 2005-10-18 Elan Pharm Inc Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
AU2004251754A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US7595318B2 (en) * 2004-01-23 2009-09-29 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
CN1980672B (zh) 2004-03-15 2011-05-04 Ptc医疗公司 用于抑制血管生成的咔啉衍生物
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
AU2005231467A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
JP2008505927A (ja) 2004-07-08 2008-02-28 イーラン ファーマスーティカルズ、インコーポレイテッド ポリマー部分を含む多価ｖｌａ−４拮抗薬
US8946444B2 (en) * 2004-11-23 2015-02-03 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
WO2006075784A1 (ja) 2005-01-13 2006-07-20 Gene Techno Science Co., Ltd. 抗α９インテグリン抗体とその用途
BRPI0611285A2 (pt) 2005-05-20 2010-08-31 Elan Pharm Inc derivados de imidazolona fenilalanina
AU2006297220B8 (en) 2005-09-29 2013-01-31 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1940827B1 (en) 2005-09-29 2011-03-16 Elan Pharmaceuticals Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
EP1996559A1 (en) 2006-02-27 2008-12-03 Elan Pharmaceuticals Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
KR101429783B1 (ko) * 2006-07-12 2014-08-18 가부시키가이샤 진 테크노 사이언스 항 인간 α９ 인테그린 항체와 그 용도
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2014201172A1 (en) * 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
KR20210128024A (ko) * 2014-12-12 2021-10-25 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 알파9 인테그린 길항제를 사용한 골수 줄기 세포 니치로부터의 hsc의 이탈 및 방출

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432307A1 (de) * 1984-09-03 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Aminosaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
WO1998037914A1 (en) * 1997-02-26 1998-09-03 Toray Industries, Inc. Remedies for hepatitis

Also Published As

Publication number Publication date
RU2220964C2 (ru) 2004-01-10
JP2001502361A (ja) 2001-02-20
ES2221183T3 (es) 2004-12-16
EP1000051B1 (en) 2004-05-19
JP2001512114A (ja) 2001-08-21
DE69824007T2 (de) 2005-05-25
NZ502578A (en) 2001-08-31
DE69812890T2 (de) 2003-12-18
JP4431717B2 (ja) 2010-03-17
CA2267175C (en) 2009-12-15
IL133636A0 (en) 2001-04-30
EP1452532A1 (en) 2004-09-01
AU8584998A (en) 1999-02-22
DE69812890D1 (de) 2003-05-08
TW533211B (en) 2003-05-21
KR100639055B1 (ko) 2006-10-27
KR20010022373A (ko) 2001-03-15
WO1999006391A1 (en) 1999-02-11
WO1999006390A1 (en) 1999-02-11
AU8605098A (en) 1999-02-22
CA2290745A1 (en) 1999-02-11
PL338521A1 (en) 2000-11-06
NO20000413L (no) 2000-03-28
EP0954519A1 (en) 1999-11-10
AR016133A1 (es) 2001-06-20
CN1265657A (zh) 2000-09-06
DE69824007D1 (de) 2004-06-24
JP2009269924A (ja) 2009-11-19
NO20000413D0 (no) 2000-01-27
EP0954519B1 (en) 2003-04-02
CA2290745C (en) 2009-09-08
ATE267188T1 (de) 2004-06-15
AU740681B2 (en) 2001-11-08
ATE236146T1 (de) 2003-04-15
CA2267175A1 (en) 1999-02-11
EP1000051A1 (en) 2000-05-17
CN1119340C (zh) 2003-08-27

Similar Documents

Publication Publication Date Title
BR9811598A (pt) &#34;compostos de carbamilóxi que inibem adesão de leucócito mediada por vla-4&#34;.
BR9811569A (pt) Compostos que inibem a adesão de leucócito mediada por vla-4
BR9811594A (pt) Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
BR9812114A (pt) Compostos do tipo fenilalanina substituìda que inibem a adesão de leucócito mediada por vla-4
BR9811573A (pt) Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4
BR9812111A (pt) Dipeptìdeo e compostos correlatos que inibem adesão de leucócito mediada por vla-4
BR9812118A (pt) Compostos do tipo 4-amino-fenilalanina que inibem adesão de leucócito mediada por vla-4
BR9811599A (pt) Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4
BR0007663A (pt) Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
BRPI0513143A (pt) antagonistas de vla-4 multivalentes compreendendo porções poliméricas
ECSP045425A (es) COMPUESTOS HETEROCÍCLICOS QUE INHIBEN LA ADHESIÓN DE LEUCOCITOS MEDIADA POR INTEGRINAS a4
EA200401561A1 (ru) Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
DE602006020754D1 (de) Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
AR029611A1 (es) Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4
AR026105A1 (es) Compuetos heteroarilo, heterociclico y ilo que

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O, 13, 24 E 25 DA LEI NO 9.279 DE 14/05/1996

B12B Appeal against refusal [chapter 12.2 patent gazette]